The Disease Risk Index (DRI) is a validated tool to categorize groups of patients undergoing allogeneic stem cell transplantation (HCT) for hematologic malignancy by disease risk. It is intended for research purposes to stratify patients in broad disease risk categories for retrospective or prospective studies.
View Publication Details
The DRI considers only disease-related parameters (i.e., disease, stage and, for some diseases, cytogenetics) and was developed only for the primary outcome of overall survival after HCT.
It does not consider patient-related variables such as age and co-morbidities and, therefore, is NOT intended to give an accurate prognosis for individual patients.
The DRI was developed using data in adult patients with hematologic malignancies and is not yet validated for pediatric patients.
Results Updated
2-year Overall Survival*: 33% (31-35)*95% confidence intervals
2-year Overall Survival*: 51% (50-52)*95% confidence intervals
2-year Overall Survival*: 23% (20-27)*95% confidence intervals
2-year Overall Survival*: 66% (63-68)*95% confidence intervals
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
Disease Note: Low-risk MDS includes refractory anemia with or without ringed sideroblasts, and refractory cytopenia with multilineage dysplasia; high-risk includes refractory anemia with excess blasts (RAEB-1 and RAEB-2).
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.